P12.03 The Time of Anti-PD-1 Infusion Improves Survival Outcomes by Fasting Conditions Simulation in Non-Small Cell Lung Cancer

Programmed cell death protein 1 (PD-1) pathway blockade represents a major breakthrough in metastatic non-small cell lung cancer (mNSCLC) treatment. However, primary and acquired resistance to PD-1 inhibition frequently occurs. Recently, we found that fasting-mimicking conditions reduced insulin-like growth factor 1 (IGF-1) levels to increase tumor immunogenicity and to sensitize lung tumors to PD-1 blockade (Ajona et al. Nature Cancer 2020). We aimed to assess whether the time of anti-PD-1 infusion, which may be associated with the fasting conditions, may correlate with clinical outcomes in mNSCLC patients.